TGFB1 and scleroderma: In the present study, we demonstrate 17,20S(OH)2pD administered by oral gavage decreases the development of dermal fibrosis and loss of subcutaneous adipose tissue, and affects the expression of key players in the TGF-β1 pathway in the BLM-induced scleroderma model of fibrosis